Arch Biopartners named to the 2022 TMX Venture 50 List of Top Performing TSX Venture Exchange Companies.
TORONTO, Feb. 24, 2022 — Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that it has been named to the 2022 TMX Venture 50 List of Top Performing TSX Venture Exchange … Read more